Yuri Kosinsky

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment.

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment.

Journal: Frontiers in pharmacology
Published: October 31, 2025

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.

Journal: Clinical pharmacology and therapeutics
Published: December 19, 2024

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease.

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease.

Journal: Clinical pharmacology and therapeutics
Published: July 26, 2024

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.

Journal: Microbiology spectrum
Published: April 12, 2022

Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.

Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.

Journal: Frontiers in immunology
Published: October 14, 2020

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.

Journal: Oncoimmunology
Published: September 16, 2020

Cycle Network Model of Prostaglandin H Synthase-1.

Cycle Network Model of Prostaglandin H Synthase-1.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 12, 2020

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study.

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study.

Journal: Frontiers in immunology
Published: February 12, 2019

Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Journal: CPT: pharmacometrics & systems pharmacology
Published: February 01, 2019

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Journal: Frontiers in immunology
Published: January 28, 2019

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

Journal: Journal for immunotherapy of cancer
Published: January 11, 2018

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies.

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies.

Journal: PloS one
Published: December 01, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026